Accéder au contenu
Merck

Principaux documents

Voir toute la documentation

S1400000

Streptomycin sulfate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Streptomycin sulfate salt

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule linéaire :
C21H39N7O12 · 1.5 H2SO4
Numéro CAS:
3810-74-0
Poids moléculaire :
728.69
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329824477
MDL number:
MFCD00037023
Beilstein/REAXYS Number:
3894995
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

grade

pharmaceutical primary standard

API family

streptomycin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

shipped in

wet ice

storage temp.

−20°C

SMILES string

OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]2[C@@H](O[C@@H](C)[C@]2(O)C=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]3NC(N)=N.CN[C@H]4[C@H](O)[C@@H](O)[C@H](CO)O[C@H]4O[C@H]5[C@@H](O[C@@H](C)[C@]5(O)C=O)O[C@@H]6[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]6NC(N)=N

InChI

1S/2C21H39N7O12.3H2O4S/c2*1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35;3*1-5(2,3)4/h2*4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28);3*(H2,1,2,3,4)/t2*5-,6-,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,21+;;;/m00.../s1

InChI key

QTENRWWVYAAPBI-YZTFXSNBSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Streptomycin sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Mode of Action: Streptomycin acts by inhibiting prokaryote protein synthesis by binding to the S12 protein of the 30S ribosomal subunit, thus preventing the transition from imitation complex to chain-elongating ribosome. This causes miscoding or inhibits initiation.

Mode of Resistance: A mutation in rpsL, a gene for S12 ribosomal protein, prevents binding of streptomycin to the ribosome. An aminoglycoside phosphotransferase also inactivates streptomycin.

Antimicrobial spectrum: Streptomycin acts against gram-negative and gram-positive bacteria.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Yu Zheng et al.
Clinical & experimental metastasis, 31(8), 921-933 (2014-09-17)
In prostate cancer metastases to bone, cancer cell-derived cytokines stimulate RANKL expression by cells of the osteoblast lineage, which in turn activates osteoclastic bone resorption. However, it is unclear whether cells of the osteoblast lineage signal back to prostate cancer
Annalisa Milano et al.
Journal of the American College of Cardiology, 64(8), 745-756 (2014-08-26)
Familial forms of primary sinus bradycardia have sometimes been attributed to mutations in HCN4, SCN5A, and ANK2. In these studies, no structural cardiac alterations were reported in mutation carriers. However, a cluster of reports in the literature describe patients presenting
Zhigang Liu et al.
Neuro-oncology, 16(6), 787-799 (2014-01-29)
Supratentorial primitive neuroectodermal tumor (sPNET) is a malignant brain tumor with poor prognosis. New model systems that replicate sPNET's molecular subtype(s) and maintain cancer stem cell (CSC) pool are needed. A fresh surgical specimen of a pediatric sPNET was directly
Afficher tous les articles scientifiques apparentés